463 related articles for article (PubMed ID: 18702968)
1. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
2. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
[TBL] [Abstract][Full Text] [Related]
3. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
4. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
[TBL] [Abstract][Full Text] [Related]
5. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
6. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
[TBL] [Abstract][Full Text] [Related]
7. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.
Petersen M; Andersen JT; Hjelvang BR; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Køber L; Torp-Pedersen C; Poulsen HE
Br J Clin Pharmacol; 2011 Apr; 71(4):556-65. PubMed ID: 21395649
[TBL] [Abstract][Full Text] [Related]
8. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.
Shin J; Lobmeyer MT; Gong Y; Zineh I; Langaee TY; Yarandi H; Schofield RS; Aranda JM; Hill JA; Pauly DF; Johnson JA
Am J Cardiol; 2007 Jan; 99(2):250-5. PubMed ID: 17223428
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
[TBL] [Abstract][Full Text] [Related]
10. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
11. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Shore S; Aggarwal V; Zolty R
J Card Fail; 2012 Dec; 18(12):919-24. PubMed ID: 23207080
[TBL] [Abstract][Full Text] [Related]
13. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
14. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B;
Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Remme WJ; Torp-Pedersen C; Cleland JG; Poole-Wilson PA; Metra M; Komajda M; Swedberg K; Di Lenarda A; Spark P; Scherhag A; Moullet C; Lukas MA
J Am Coll Cardiol; 2007 Mar; 49(9):963-71. PubMed ID: 17336720
[TBL] [Abstract][Full Text] [Related]
16. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
[TBL] [Abstract][Full Text] [Related]
17. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Remme WJ; Cleland JG; Erhardt L; Spark P; Torp-Pedersen C; Metra M; Komajda M; Moullet C; Lukas MA; Poole-Wilson P; Di Lenarda A; Swedberg K
Eur J Heart Fail; 2007 Nov; 9(11):1128-35. PubMed ID: 17716943
[TBL] [Abstract][Full Text] [Related]
18. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
Pasternak B; Svanström H; Melbye M; Hviid A
JAMA Intern Med; 2014 Oct; 174(10):1597-604. PubMed ID: 25173681
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
Levy AR; Briggs AH; Demers C; O'Brien BJ
Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
[TBL] [Abstract][Full Text] [Related]
20. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]